BIO-RAD LABORATORIES -CL B (BIO.B) Stock Fundamental Analysis
USA - NYSE:BIO.B - US0905721082 - Common Stock
321.12 USD
+36.24 (+12.72%)
Taking everything into account, BIO.B scores 4 out of 10 in our fundamental rating. BIO.B was compared to 57 industry peers in the Life Sciences Tools & Services industry. BIO.B is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. BIO.B does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
BIO.B had positive earnings in the past year.
In the past year BIO.B had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BIO.B reported negative net income in multiple years.
BIO.B had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BIO.B has a Return On Assets of 3.12%. This is in the better half of the industry: BIO.B outperforms 70.18% of its industry peers.
The Return On Equity of BIO.B (4.47%) is better than 70.18% of its industry peers.
Looking at the Return On Invested Capital, with a value of 2.36%, BIO.B is in line with its industry, outperforming 59.65% of the companies in the same industry.
BIO.B had an Average Return On Invested Capital over the past 3 years of 2.69%. This is significantly below the industry average of 14.93%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.12% | ||
| ROE | 4.47% | ||
| ROIC | 2.36% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
With a decent Profit Margin value of 12.49%, BIO.B is doing good in the industry, outperforming 78.95% of the companies in the same industry.
BIO.B's Operating Margin of 11.30% is fine compared to the rest of the industry. BIO.B outperforms 68.42% of its industry peers.
BIO.B's Operating Margin has been stable in the last couple of years.
The Gross Margin of BIO.B (53.00%) is comparable to the rest of the industry.
BIO.B's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.3% | ||
| PM (TTM) | 12.49% | ||
| GM | 53% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
BIO.B has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
BIO.B has less shares outstanding than it did 1 year ago.
BIO.B has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, BIO.B has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.18 indicates that BIO.B is not in any danger for bankruptcy at the moment.
BIO.B has a better Altman-Z score (3.18) than 70.18% of its industry peers.
BIO.B has a debt to FCF ratio of 3.46. This is a good value and a sign of high solvency as BIO.B would need 3.46 years to pay back of all of its debts.
BIO.B's Debt to FCF ratio of 3.46 is fine compared to the rest of the industry. BIO.B outperforms 73.68% of its industry peers.
A Debt/Equity ratio of 0.17 indicates that BIO.B is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.17, BIO.B perfoms like the industry average, outperforming 57.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 3.46 | ||
| Altman-Z | 3.18 |
ROIC/WACC0.23
WACC10.09%
2.3 Liquidity
BIO.B has a Current Ratio of 5.12. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
BIO.B has a Current ratio of 5.12. This is in the better half of the industry: BIO.B outperforms 68.42% of its industry peers.
BIO.B has a Quick Ratio of 3.67. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.67, BIO.B is in the better half of the industry, outperforming 64.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.12 | ||
| Quick Ratio | 3.67 |
3. Growth
3.1 Past
The earnings per share for BIO.B have decreased by -7.11% in the last year.
The Earnings Per Share has been growing slightly by 7.84% on average over the past years.
BIO.B shows a decrease in Revenue. In the last year, the revenue decreased by -0.33%.
Measured over the past years, BIO.B shows a small growth in Revenue. The Revenue has been growing by 2.11% on average per year.
EPS 1Y (TTM)-7.11%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-16.08%
Revenue 1Y (TTM)-0.33%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%2.06%
3.2 Future
The Earnings Per Share is expected to decrease by -2.55% on average over the next years.
BIO.B is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.48% yearly.
EPS Next Y-5.49%
EPS Next 2Y0.38%
EPS Next 3Y3.62%
EPS Next 5Y-2.55%
Revenue Next Year0.65%
Revenue Next 2Y1.77%
Revenue Next 3Y2.31%
Revenue Next 5Y1.48%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 31.92, which means the current valuation is very expensive for BIO.B.
Based on the Price/Earnings ratio, BIO.B is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
BIO.B is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.77, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 30.91, which means the current valuation is very expensive for BIO.B.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BIO.B indicates a somewhat cheap valuation: BIO.B is cheaper than 68.42% of the companies listed in the same industry.
BIO.B is valuated rather expensively when we compare the Price/Forward Earnings ratio to 23.23, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.92 | ||
| Fwd PE | 30.91 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BIO.B is valued cheaply inside the industry as 80.70% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.01 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)4.07
EPS Next 2Y0.38%
EPS Next 3Y3.62%
5. Dividend
5.1 Amount
No dividends for BIO.B!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:BIO.B (10/21/2025, 4:10:02 PM)
321.12
+36.24 (+12.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.73%
Inst Owner Change0%
Ins Owners3.84%
Ins Owner ChangeN/A
Market Cap8.69B
Analysts78.18
Price Target369.39 (15.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.02%
Min EPS beat(2)38.97%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)40.05%
Min EPS beat(4)0.1%
Max EPS beat(4)72.05%
EPS beat(8)7
Avg EPS beat(8)26.32%
EPS beat(12)8
Avg EPS beat(12)16.87%
EPS beat(16)12
Avg EPS beat(16)20.5%
Revenue beat(2)2
Avg Revenue beat(2)2.99%
Min Revenue beat(2)1.11%
Max Revenue beat(2)4.87%
Revenue beat(4)3
Avg Revenue beat(4)1.42%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-1.19%
Revenue beat(12)3
Avg Revenue beat(12)-1.6%
Revenue beat(16)6
Avg Revenue beat(16)-0.34%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)17.09%
EPS NQ rev (3m)-22.41%
EPS NY rev (1m)14.35%
EPS NY rev (3m)11.99%
Revenue NQ rev (1m)3.05%
Revenue NQ rev (3m)-1.08%
Revenue NY rev (1m)2.91%
Revenue NY rev (3m)2.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.92 | ||
| Fwd PE | 30.91 | ||
| P/S | 3.4 | ||
| P/FCF | 25.01 | ||
| P/OCF | 16.25 | ||
| P/B | 1.22 | ||
| P/tB | 1.41 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.06
EY3.13%
EPS(NY)10.39
Fwd EY3.24%
FCF(TTM)12.84
FCFY4%
OCF(TTM)19.76
OCFY6.15%
SpS94.39
BVpS263.44
TBVpS227.28
PEG (NY)N/A
PEG (5Y)4.07
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.12% | ||
| ROE | 4.47% | ||
| ROCE | 2.99% | ||
| ROIC | 2.36% | ||
| ROICexc | 2.75% | ||
| ROICexgc | 3.12% | ||
| OM | 11.3% | ||
| PM (TTM) | 12.49% | ||
| GM | 53% | ||
| FCFM | 13.61% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexcg growth 3Y8.21%
ROICexcg growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score6
Asset Turnover0.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 3.46 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 7.33% | ||
| Interest Coverage | -6.2 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 108.94% | ||
| Current Ratio | 5.12 | ||
| Quick Ratio | 3.67 | ||
| Altman-Z | 3.18 |
F-Score6
WACC10.09%
ROIC/WACC0.23
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.11%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-16.08%
EPS Next Y-5.49%
EPS Next 2Y0.38%
EPS Next 3Y3.62%
EPS Next 5Y-2.55%
Revenue 1Y (TTM)-0.33%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%2.06%
Revenue Next Year0.65%
Revenue Next 2Y1.77%
Revenue Next 3Y2.31%
Revenue Next 5Y1.48%
EBIT growth 1Y-15.48%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.54%
EBIT Next 3Y15.21%
EBIT Next 5Y7.17%
FCF growth 1Y125.65%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y86.4%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%